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Abstract 
Surface acoustic wave (SAW) biosensors based on horizontally polarized surface shear waves enable label-free, sensitive and 
cost-effective detection of biomolecules in real time. Binding reactions on the sensor surface are detected by determining changes
in surface wave velocity caused mainly by mass loading in the sensing layer. Typically, SAW devices are coated with 
biochemically sensitive layers including analyte-specific capture molecules (e.g., antibodies) or ligands. The covalent binding of 
antibodies to intermediate hydrogel layers (e.g., dextran or polyethylene glycol) tends to result in undirected orientation of 
capture molecules and leading to a lower signal response in a subsequent analyte binding experiment. Therefore, a coupling 
procedure was developed using two linkers, neutravidin and biotinylated protein A, allowing directed orientation of capture 
antibodies. This assembly enables label-free and direct detection of the breast cancer marker HER-2/neu at a concentration of 
10 ng/ml (threshold: 13-20 ng/ml). 
© 2009 Published by Elsevier Ltd. 
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1. Introduction 
HER-2/neu (human epidermal growth factor receptor 2), also known as ErbB2, is a protein marker for breast 
cancer, which is currently used to predict response to trastuzumab (Herceptin®)-based treatment and to prognosticate 
course of disease [1]. There are two possibilities to measure the molecular state of HER-2/neu in patients: 
immunohistochemistry (IHC) staining of the whole cell membrane receptor in tissue sections obtained from biopsy 
or detection of the concentration of the extracellular domain (ECD) of HER-2/neu (HER-2/neu-ECD), which is shed 
in serum, via ELISA featuring the advantage of a biopsy-free analysis. However it exists a commercial available 
ELISA from Bayer [2], there is still a need for a direct, label-free, rapid and cost effective method for the detection 
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of HER-2/neu-ECD in serum. This can be met by SAW biosensors, which already have been applied successfully to 
detect proteins, DNA and bacteria [3]. We developed a SAW biosensor system consisting of a SAW device 
embedded in a flow cell integrated in a flow injection analysis (FIA) system. This set-up was used successfully in 
several affinity binding experiments [3-5]. The surface modification was adapted for the detection of low 
concentrations of clinical relevant protein marker HER-2/neu-ECD. 
2. Experimental 
2.1. SAW device and fluidic setup 
A shear horizontal SAW resonator based on a small (4 x 4 mm²) 36°YX-LiTaO3 device with gold transducers and 
a frequency of operation of 428.5 MHz was used. SAW measurements were performed in an oscillator circuit 
developed in-house with the SAW resonator as frequency-determining element. Details of the set-up have been 
described earlier [6]. A flow cell was designed in which the SAW device was mounted upside down onto isolated 
contact pads on the electronic board and coupled capacitively [6;7]. A flow channel between the contact pads 
allowed the fluid to pass the SAW sensor. 
2.2. Sensor surface modification 
Chemicals were obtained from Merck, Germany and Sigma-Aldrich, Germany, unless otherwise noted. The 
antibody anti-HER-2/neu (monoclonal mouse IgG; R&D Systems, Germany) was used as capture molecule. 
Neutravidin (Thermo Scientific Fisher, Germany) was used as first linker; biotinylated protein A (Thermo Scientific 
Fisher, Germany) was used as second linker. 
2.2.1. Covalent binding of intermediate hydrogel layer 
All SAW devices used in the following experiments were first coated with 0.1 μm parylene C to obtain a 
chemically homogeneous surface [8]. The parylene C layer was activated by oxidation via plasma treatment and 
subsequent silanization with (3-glycidyloxypropyl)trimethoxysilane. After rinsing with acetone the sensors were 
immediately used for hydrogel coupling [5; 9]. 
Dicarboxy polyethylene glycol (DC-PEG), Mr 2,000 (Rapp Polymere, Germany) was immobilized as follows: 
10 μl of a solution of DC-PEG in dichloromethane, c = 2 mg/ml, was applied on the activated sensor surfaces. After 
evaporation of the solvent, the sensors were heated to 70 °C for 20 h, rinsed with bidistilled water and dried. 
Amino-biotin polyethylene glycol (AB-PEG), Mr 3,000 (Rapp Polymere, Germany) was immobilized as follows: 
10 μl of an aqueous solution AB-PEG, c = 3 mg/ml, was applied on the activated sensor surfaces. After reaction for 
20 h at room temperature, the sensors were rinsed with bidistilled water and dried. 
2.2.2. Covalent immobilization procedure on carboxylated surfaces 
After each modification step the sensors were rinsed with phosphate buffered saline (PBS). First the carboxylated 
surfaces (DC-PEG) were activated with an aqueous solution of 0.05 M N-hydroxy succinimide and 0.2 M N-(3-
dimethylaminopropyl)-N`-ethylcarbodiimide hydrochloride for 10 min. Second the surface was incubated with 
1 mg/ml anti-HER-2 or 50 μg/ml neutravidin in acetate buffer, pH 5, for 30 min. Third the remaining active groups 
on the surface were deactivated by treatment with a solution of 1 M ethanolamine, pH 8.5, for 10 min. After that, 
sensors with immobilized antibodies were immediately used for the subsequent assays. Sensors with immobilized 
neutravidin were treated with biotinylated protein A, c = 10 μg/ml, for 30 min. Then the sensors were treated with 
anti-HER-2/neu, c = 20 μg/ml, for 30 min. After that sensors were immediately used for the binding assay.  
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2.2.3. Non-covalent immobilization procedure on biotinylated surfaces 
After each modification step the sensors were rinsed with PBS. First the non-covalent coupling of neutravidin, 
c = 50 μg/ml, to the biotin groups of AB-PEG was performed for 30 min. Then the sensors were treated with 
biotinylated protein A, c = 10 μg/ml, for 30 min and treated with anti-HER-2, c = 5 μg/ml, for 30 min. After that the 
sensors were immediately used for the binding assay.  
2.3. SAW biosensor measurements 
Recombinant human (rh) HER-2/neu (R&D Systems, Germany) was used as analyte. Experiments were 
performed with the FIA system described elsewhere [6]. PBS was used as carrier stream, the flow rate was set to 
0.05 ml/min. Samples were loaded in the sample loop, injected into the carrier stream via the injection valve, and 
transported to the sensor. The injection interval was set to 60-300 s. After each sample injection the sensor was 
rinsed in the carrier stream for 5 min. Shielding against unspecific binding was determined by injection of a solution 
of BSA (Serva, Germany), c = 1 mg/ml, in the PBS carrier stream. If the BSA signal was determined to be 
negligible, samples containing c = 0 (0.001; 0.01; 0.1) μg/ml HER-2/neu in PBS were injected subsequently in the 
carrier stream. Signal heights were calculated from the SAW signal response curves as difference between the SAW 
signals after and before the injection interval.  
3. Results and discussion 
For the detection of HER-2/neu-ECD, the sensor surface was modified with a corresponding monoclonal 
antibody (anti-HER-2). Unspecific binding was prevented by coupling the binding molecules via an intermediate 
polyethylene glycol (PEG) hydrogel layer on the sensor surface. Our “standard” coupling procedure of the antibody 
anti-HER-2/neu via carbodiimid chemistry on DC-PEG  did not enable the detection of HER-2/neu-ECD up to 
100 ng/ml (figure 1, blue). 
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Fig. 1: Detection of HER-2/neu-ECD. Comparison of signal response (see columns) based on different immobilization methods (see schemes with 
corresponding colors of frames). Undirected orientation with covalent immobilization of  anti-HER-2/neu  on DC-PEG (blue) and directed
orientation of anti-HER-2/neu via covalent (green) and affinity (brown) coupling of neutravidin on DC-PEG and AB-PEG, respectively, prior to 
binding of biotinylated protein A. Samples containing 1 (10; 100) ng/ml HER-2/neu-ECD were applied subsequently on each sensor. Columns 
represent means , error bars represent standard abbreviation values out of three measurements.  
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Therefore, we developed an immobilization method of anti-HER-2/neu via two linkers, neutravidin and 
biotinylated protein A. We compared the effects of covalent coupling and affinity coupling of the first linker, 
neutravidin, in the subsequent HER-2/neu-ECD assay. Affinity coupling of neutravidin, via AB-PEG, prior to 
binding of biotinylated protein A and anti-HER-2/neu (figure 2, brown), led to higher signal responses in this assay 
than covalent coupling of neutravidin to DC-PEG prior to binding of biotinylated protein A and anti-HER-2/neu
(figure 2, green). The optimized surface modification procedure enabled the detection of 10 ng/ml HER-2/neu-ECD. 
4. Conclusions 
In this work the effect of different strategies of antibody immobilization on the signal response of SAW 
biosensors in a subsequent assay was investigated. An efficient coupling procedure was developed for the affinity 
system anti-HER-2/neu and HER-2/neu-ECD, where the latter is a potential biomarker for breast cancer. The 
optimized protocol based on site-directed antibody coupling via two linkers, neutravidin and biotinylated protein A, 
where neutravidin was coupled via affinity binding to AB-PEG. Based on this procedure, 10 ng/ml HER-2/neu-ECD
could be detected. The cut-off value for diagnostic applications is 13-20 ng/ml. The next step would be the testing of 
this surface modification procedure with real samples, such as serum. As antibodies are widely used as biospecific 
capture molecules in binding assays, our findings should also be valid for other biosensor principles and applications 
in clinical diagnostic.  
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